Ab Science(OTC) ABSCF

AB Science S.A. is a pharmaceutical company focused on the discovery, development, and commercialization of protein kinase inhibitors for human and animal medicine. The company is advancing its flagship product, masitinib, through extensive clinical trials for various serious conditions.

Products and Services

• Masitinib, a tyrosine kinase inhibitor for multiple serious conditions
• AB8939, a synthetic microtubule destabilizer for acute myeloid leukemia
• AB20001, evaluating masitinib with isoquercetin for COVID-19 treatment

Growth Outlook

• Masitinib is in Phase III trials for prostate and pancreatic cancer
• Potential expansion into COVID-19 treatment with ongoing Phase II trials
• Commercial availability in Europe under the brand name Masivet

Financial Highlights

• Recent quarterly revenue of 658,753 EUR, showing growth from previous quarters
• Net income of 3,618,644 EUR in the latest quarter, indicating positive momentum
• Cash and cash equivalents reached 10,175,187 EUR, providing operational flexibility

AB Science S.A. operates in the healthcare sector, specifically within the drug manufacturing industry, and has a market capitalization of approximately 82 million USD. The company has been actively involved in clinical trials for its lead product, masitinib, which is being tested for a range of serious conditions, including various cancers and neurodegenerative diseases. The ongoing trials and the potential for new therapeutic applications position AB Science as a company with significant growth prospects. Recent financial performance indicates a positive trend, with increasing revenue and net income, which may attract investor interest. The company's strong cash position further supports its ability to fund ongoing research and development initiatives.